NANOMUNITY

Established in 2023 by Dr David Béchard PhD, serial biotech entrepreneur, and Dr Patrick Chames PhD, CNRS Research Director, Director of the Antibody Therapeutics and Immunotargeting (ATI) team at Centre de Recherche en Cancérologie de Marseille (CRCM), Nanomunity is a privately-held, biopharmaceutical company that is actively engaged in the discovery and development of first-in class and multifunctional immunotherapy products for treating cancer. We are addressing one of the most pressing challenges in cancer immunotherapy by developing unique drugs that uncouple gain of efficacy for treating ICB-resistant cancers and immunotherapy-related adverse effects. Our team brings success from biotech pharma, and academia to Nanomunity. Nanomunity has been supported by Aix-Marseille University, SATT Sud Est, Impulse Incubator, Eurobiomed, BPI, CRCM and Remora Biotech Venture Builder. The company is also part of the Marseille Immunology Biocluster (MIB, Health Innovation 2030 plan).

Medicine

0.00 K€